A PHASE 1B/2, MULTI-CENTER, DOUBLE-BLIND (PRINCIPAL INVESTIGATORS AND STUDY SUBJECTS BLINDED, SPONSOR UNBLINDED), PLACEBO- CONTROLLED, RANDOMIZED, SINGLE-ASCENDING DOSE STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DS-1040B IN SUBJECTS WITH ACUTE ISCHEMIC STROKE

September 24, 2018
https://clinicaltrials.gov/ct2/show/NCT02586233
Stroke
Principal Investigator: Daniel J Miller, MD
acute, ischemic, stroke
Accepting Participants
(313)916-8071